once monthly glp 1 agonist ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of obesity medicine: triple agonists, oral GLP-1s, injections, and therapies targeting obesity, diabetes, and GLP-1 Agonists: A Comprehensive Overview

[DOI] [PubMed] [Google Scholar] 36.Holst J.J

[DOI] [PMC free article] [PubMed] [Google Scholar] 56.Schmidt H.D., Mietlicki-Baase E.G., Ige K.Y., Maurer J.J., Reiner D.J., Zimmer D.J., Van Nest D.S., Guercio L.A., Wimmer M.E., Olivos D.R., et al

References 1 AbtahiS.HowellE.CurrieP

Before starting any research protocol, know how you would handle a significant adverse reaction

This makes DPC-based therapies particularly promising for long-term and large-scale hair regeneration

This new trial built on a previous one published in NEJM last fall (I previously reviewed here) for the same indication, but the only difference was the inclusion of people with diabetes